Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of HTL0018318 Solution vs Capsule
NCT02958696Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HTL0018318 in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) (3 cohorts), sponsored by Nxera Pharma. Primary endpoints: Maximum plasma concentration and Area under the curve. Started Oct 2016; status: completed.
02
Drugs
HTL0018318
03
Conditions
Alzheimer's disease (AD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT02958696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958696.